ArticleEuropean journal of pharmacology2011
Resveratrol modifies risk factors for coronary artery disease in swine with metabolic syndrome and myocardial ischemia.
Article in European journal of pharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 50 citations in OpenAlex.
- Mechanistic Basis for the Role of Phytochemicals in Inflammation-Associated Chronic Diseases.Molecules (Basel, Switzerland) · 2022Review
- Peroxisome Proliferator-Activated Receptor-Gamma (PPAR-ɣ): Molecular Effects and Its Importance as a Novel Therapeutic Target for Cerebral Ischemic Injury.Neurochemical research · 2021Review
- Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies.Pharmacology & therapeutics · 2019Review
- The Effects of Resveratrol in the Treatment of Metabolic Syndrome.International journal of molecular sciences · 2019Review
- Biomarkers of Oxidative Stress in Metabolic Syndrome and Associated Diseases.Oxidative medicine and cellular longevity · 2019Review
- Elastic aortic wrap reduced aortic stiffness by partially alleviating the impairment of cholesterol efflux capacity in pigs.Journal of diabetes and metabolic disorders · 2018Article
- Successful rebuilding after disaster, even in the heart, starts with infrastructure.Journal of thoracic disease · 2018Article
- Challenges in Analyzing the Biological Effects of Resveratrol.Nutrients · 2016Review
- Resveratrol and Cardiovascular Diseases.Nutrients · 2016Review
- Novel nutraceutic therapies for the treatment of metabolic syndrome.World journal of diabetes · 2016Review
- Early Cellular Changes in the Ascending Aorta and Myocardium in a Swine Model of Metabolic Syndrome.PloS one · 2016Article
- Modulation of Hypercholesterolemia-Induced Oxidative/Nitrative Stress in the Heart.Oxidative medicine and cellular longevity · 2016Review
- Retinol binding protein 4 in relation to diet, inflammation, immunity, and cardiovascular diseases.Advances in nutrition (Bethesda, Md.) · 2015Review
- The effects of resveratrol in rats with simultaneous type 2 diabetes and renal hypertension: a study of antihypertensive mechanisms.Iranian journal of medical sciences · 2015Article
- Investigating the effects of resveratrol on chronically ischemic myocardium in a swine model of metabolic syndrome: a proteomics analysis.Journal of medicinal food · 2015Article
- Resveratrol regulates autophagy signaling in chronically ischemic myocardium.The Journal of thoracic and cardiovascular surgery · 2014Article
- Synergistic effects of polyphenols and methylxanthines with Leucine on AMPK/Sirtuin-mediated metabolism in muscle cells and adipocytes.PloS one · 2014Article
- Effects of the PPAR-β/δ agonist GW0742 during resuscitated porcine septic shock.Intensive care medicine experimental · 2013Article
- Does resveratrol improve insulin signaling in chronically ischemic myocardium?The Journal of surgical research · 2013Article
- Metabolic syndrome is not a predictor for cardiovascular events in Japanese patients with diabetes mellitus asymptomatic for coronary artery disease: a retrospective analysis of the J-ACCESS-2 study.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
Abstract
Resveratrol has been purported to modify risk factors for obesity and cardiovascular disease. We sought to examine the effects of resveratrol in a porcine model of metabolic syndrome and chronic myocardial ischemia. Yorkshire swine were fed either a normal diet (control), a high cholesterol diet (HCD), or a high cholesterol diet with supplemental resveratrol (HCD-R; 100mg/kg/day) for 11 weeks. After 4 weeks of diet modification a baseline cardiovascular MRI was performed and an ameroid constrictor was placed on the left circumflex coronary artery of each animal to induce chronic myocardial ischemia. At 7 weeks, a second cardiovascular MRI was performed and swine were sacrificed and myocardial tissue harvested. Resveratrol supplementation resulted in lower body mass indices, serum cholesterol, and C-reactive protein levels, improved glucose tolerance and endothelial function, and favorably augmented signaling pathways associated with myocardial metabolism. Interestingly, serum tumor necrosis factor-α levels were not influenced by resveratrol treatment. Immunoblotting for markers of metabolism demonstrated that insulin receptor substrate-1, glucose transporters 1 and 4, and phospho-AMPK were increased in the HCD-R group. Peroxisome proliferator-activated receptor γ and retinol binding protein 4 were downregulated in the HCD-R group as compared to the HCD group. Myocardial perfusion and function at rest as assessed with magnetic resonance imaging were not different between groups. By favorably influencing risk factors, resveratrol may decrease the burden of chronic metabolic disease and improve cardiovascular health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.